|
|
| Date |
Subject |
| 07/10/2008 |
New Phase II data on NVA237, a novel once-daily treatment for COPD, show promising efficacy and tolerability with potentially faster onset than tiotropium |
| 06/10/2008 |
New study shows potential benefits of innovative Xolair® anti-IgE therapy in treating children suffering from moderate-to-severe allergic asthma |
| 30/09/2008 |
Once-yearly Aclasta® approved in EU to treat osteoporosis in men and to reduce risk of new fractures following hip fracture both in men and postmenopausal women |
| 25/09/2008 |
Novartis starts ''squeeze out'' procedure for remaining Speedel shares |
| 19/09/2008 |
Novartis MF59®-adjuvanted vaccine rapidly induces protective antibody levels against diverse strains of avian flu |
| 16/09/2008 |
Latest RAD001 study results show further increase in time without tumor growth in patients with advanced kidney cancer |
| 15/09/2008 |
Novartis receives FDA priority review for Coartem®, potentially the first artemisinin-based combination treatment (ACT) for malaria in the US |
| 13/09/2008 |
RAD001 combined with Sandostatin® LAR® and as monotherapy controls growth of rare pancreatic neuroendocrine tumors |
| 10/09/2008 |
New Phase II data show Novartis investigational Meningitis B vaccine may also protect infants six months and older |
| 09/09/2008 |
Data show Galvus® better tolerated by patients with type 2 diabetes, with no weight gain, a favorable cardiovascular profile and equal efficacy compared to widely-used TZDs |
| 09/09/2008 |
RAD001 granted priority review in the US based on potential to fill unmet medical need in patients with advanced kidney cancer |
| 03/09/2008 |
Rasilez® , first-in-class direct renin inhibitor, lowers high blood pressure more effectively than diuretic in obese patients |
| 03/09/2008 |
Sandoz receives FDA approval for Omnitrope® Pen 10 with liquid cartridge |
| 29/08/2008 |
Novartis decides not to pursue further development of Aurograb(TM) |
| 27/08/2008 |
Glivec receives FDA priority review as first therapy to reduce recurrence of gastrointestinal stromal tumors after surgery |
| 27/08/2008 |
NICE final guidance recommends Lucentis® as cost-effective treatment for wet AMD, a leading cause of blindness |
| 07/08/2008 |
Novartis begins shipment to US of Fluvirin® Influenza Virus Vaccine with three new strains for the 2008-2009 influenza season |
| 04/08/2008 |
Single-pill combinations Diovan HCT® and Exforge® approved in US as first-line treatments for high blood pressure |
| 28/07/2008 |
Exforge® helps nearly twice as many patients control their high blood pressure compared to amlodipine alone |
| 25/07/2008 |
Once-yearly Aclasta® recommended in EU to treat male osteoporosis and reduce risk of new fractures in patients after hip fracture |
| 17/07/2008 |
Novartis gains momentum with strong performance in first half of 2008 from portfolio focused on growth areas of healthcare |
| 11/07/2008 |
Novartis enters strategic partnership with Lonza to accelerate growth of biologics pipeline |
| 10/07/2008 |
Novartis buys additional 51.7% stake in Speedel and announces plans to acquire remaining shares in a mandatory public tender offer |
| 08/07/2008 |
Novartis completes acquisition of 25% stake in Alcon from Nestlé, first step toward majority ownership of the world leader in eye care |
| 02/07/2008 |
Novartis Pharmaceuticals Corporation to Appeal Judgment in Alabama Pricing Case |
| 24/06/2008 |
Novartis Institute for Tropical Diseases and Global Alliance for TB Drug Development announce five-year collaboration targeted to accelerate TB treatment R&D |
| 17/06/2008 |
Rasilez®[*] ASPIRE HIGHER clinical program expands to 35,000 patients in 14 trials, the largest cardio-renal outcomes program ever |
| 13/06/2008 |
Higher initial dose of Glivec achieved better early responses than standard dose for patients with chronic myeloid leukemia |
| 12/06/2008 |
Novartis recommends rejection of ''mini-tender'' offer by TRC Capital for American Depositary Shares |
| 10/06/2008 |
Novartis successfully issues two Swiss franc benchmark bonds totaling CHF 1.5 billion |
| 05/06/2008 |
Leading blood pressure medication Diovan® with diuretic reduces key sign of artery ageing which is linked to risk of heart attack and stroke |
| 05/06/2008 |
FDA broadens US indication for once-yearly Reclast® as only osteoporosis treatment approved for prevention of fractures after a hip fracture |
| 04/06/2008 |
New data show potential of Rasilez®* to protect kidneys from damage independent of its proven ability to lower blood pressure |
| 04/06/2008 |
Novartis gains rights to promising hospital antibiotic in clinical development through full acquisition of Protez Pharmaceuticals |
| 04/06/2008 |
Novartis presents full pipeline of novel vaccines addressing significant unmet needs |
| 02/06/2008 |
Early data presented at ASCO show potential of RAD001 to enhance efficacy of, and overcome resistance to, breast cancer treatments |
| 31/05/2008 |
Major independent trial demonstrates significant anticancer benefit of Zometa® in women with early-stage breast cancer |
| 26/05/2008 |
Extavia® approved in European Union for treatment of multiple sclerosis, first in planned portfolio of therapies from Novartis |
| 19/05/2008 |
RAD001 more than doubles time without tumor growth after failure of standard treatment in patients with advanced kidney cancer |
| 15/05/2008 |
Strength and innovation of Novartis Oncology products and pipeline with potential to improve patient treatment demonstrated by more than 170 abstracts at ASCO annual meeting |
| 15/05/2008 |
New data show Tekturna HCT® is twice as effective at reducing blood pressure than the diuretic HCT alone |
| 14/05/2008 |
In a Phase II study, Novartis Meningitis B vaccine has potential to produce a protective immune response in infants[1], the age group most at risk |
| 14/05/2008 |
Significant blood pressure reductions seen in difficult-to-treat, black patients receiving Exforge®-based therapy[1] |
| 06/05/2008 |
Novartis Menveo® vaccine shows superior immune response against four types of meningitis disease in pivotal phase III trial |
| 28/04/2008 |
Breakthrough technique pioneered at Novartis research institute restores light sensitivity in damaged retinas |
| 23/04/2008 |
Novartis announces 20% average reduction in price of malaria drug Coartem® to further accelerate access in malaria-endemic regions |
| 21/04/2008 |
Novartis reports higher sales and earnings in first quarter of 2008 showing healthcare portfolio well on the way to new growth cycle |
| 15/04/2008 |
FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment |
| 15/04/2008 |
Patients with early Parkinson's disease show better symptom control[1] and improvements in daily activities[1] with Stalevo than levodopa/carbidopa |
| 11/04/2008 |
Study shows once-yearly Aclasta® better than risedronate at increasing bone mass in patients with osteoporosis caused by glucocorticoids |
| 11/04/2008 |
ASA404, a novel cancer agent, begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death |
| 08/04/2008 |
ACZ885, a new biological drug in development, shows potential in treating serious life-long autoinflammatory diseases |
| 07/04/2008 |
Novartis to further strengthen its healthcare portfolio by acquiring 25% stake in Alcon from Nestlé with right to take over majority ownership of the world leader in eye care |
| 31/03/2008 |
Rasilez®* , the first-in-class direct renin inhibitor, reduces left ventricular hypertrophy, a powerful predictor of heart disease |
| 12/03/2008 |
Sandoz enhances patient access with launch of Omnitrope(TM) Pen 5 with liquid cartridge |
| 10/03/2008 |
Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy |
| 28/02/2008 |
Everolimus (RAD001) significantly extends progression-free survival in advanced kidney cancer patients after failure of other targeted therapy |
| 26/02/2008 |
Novartis shareholders approve all resolutions at 2008 Annual General Meeting, including 19% dividend increase |
| 25/02/2008 |
Eucreas®, a single-tablet combination of Galvus® and metformin, set for launch in first EU countries as new treatment for type 2 diabetes |
| 22/02/2008 |
New Novartis Research Institute first to focus on innovative vaccines for the developing world |
| 01/02/2008 |
Novartis announces proposals for shareholder approval at next Annual General Meeting |
| 01/02/2008 |
Galvus®, a new treatment for patients with type 2 diabetes, receives European approval for label update paving the way for EU launches |
| 31/01/2008 |
Novartis files its Form 20-F annual report with the US Securities and Exchange Commission |
| 21/01/2008 |
Tekturna HCT®, a single-tablet combination of Tekturna®* and a diuretic, receives US approval for treatment of high blood pressure |
| 17/01/2008 |
Novartis achieves record results in 2007 underscoring benefits of strategic healthcare portfolio |
| 08/01/2008 |
New data show Menveo(TM) to be the first quadrivalent meningococcal vaccine to provide immunogenicity in infants |
| 17/12/2007 |
Galvus®, a new oral treatment for type 2 diabetes, receives positive opinion following changes to European prescribing information |
| 13/12/2007 |
Novartis launches strategic initiative to improve competitiveness in a dynamically changing healthcare environment |
| 09/12/2007 |
New data show Glivec® halts progression to advanced stages of life-threatening form of leukemia in sixth year of treatment |
| 02/12/2007 |
Novartis further strengthens biologics capabilities in expansion of MorphoSys collaboration |
| 30/11/2007 |
Novartis completes its fifth share repurchase program |
| 28/11/2007 |
Tasigna® gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies |
| 21/11/2007 |
CIBA Vision, the eye care unit of Novartis, announces settlement of patent litigation with CooperVision, Inc. |
| 19/11/2007 |
United Kingdom and Germany suspend marketing and sale of Prexige® pending outcome of European regulatory review |
| 15/11/2007 |
New data for Menveo(TM) vaccine show excellent immune response and broad protection for infants against meningococcal meningitis |
| 06/11/2007 |
New Galvus® clinical data reinforces efficacy profile; safety update provided to regulatory agencies |
| 29/10/2007 |
Tasigna® receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies |
| 22/10/2007 |
Voltaren® Gel receives US regulatory approval as the first approved topical prescription treatment for pain associated with osteoarthritis |
| 18/10/2007 |
Novartis delivers record earnings in first nine months of 2007 thanks to strong operational performance and divestment gains |
| 05/10/2007 |
Aclasta® receives European approval as first once-yearly treatment for postmenopausal osteoporosis |
| 28/09/2007 |
Novartis and Massachusetts Institute of Technology (MIT) in new partnership aimed at transforming pharmaceutical manufacturing |
| 28/09/2007 |
Galvus® receives European approval as new treatment for type 2 diabetes with broad range of indications |
| 27/09/2007 |
Prexige® receives ''not approvable'' letter in the US despite being one of the most studied COX-2 inhibitors |
| 24/09/2007 |
Exelon® patch receives European Union approval, the first skin patch therapy to treat Alzheimer's disease |
| 21/09/2007 |
Tasigna® recommended for European approval to treat rare form of leukemia no longer responding to Glivec® |
| 21/09/2007 |
Eucreas®, a single-tablet combination of Galvus® and metformin, recommended for EU approval for type 2 diabetes |
| 18/09/2007 |
First osteoporosis study in patients with hip fracture finds once-yearly Aclasta®-Reclast® prevents additional fractures and improves survival |
| 17/09/2007 |
New data for Galvus® provide further evidence of robust efficacy and tolerability in treating patients with type 2 diabetes |
| 14/09/2007 |
Novartis completes agreement with Bayer Schering related to Betaseron® rights and manufacturing |
| 10/09/2007 |
US federal appeals court temporarily stops Teva from selling its generic version of the Novartis medicine Famvir® |
| 07/09/2007 |
Novartis to defend its intellectual property rights for Famvir® despite an at-risk generic launch in US |
| 05/09/2007 |
Cubicin® receives European approval to expand use to treating two additional types of life-threatening hospital infections |
| 03/09/2007 |
Novartis completes divestment program with transfer of Gerber baby foods business |
| 02/09/2007 |
Study shows Rasilez®, the first and only approved direct renin inhibitor, reduces a marker of heart failure severity and is well-tolerated |
| 31/08/2007 |
Sandoz Receives European Commission Approval for biosimilar epoetin alfa |
| 29/08/2007 |
Novartis announces the retirement of Urs Baerlocher |
| 27/08/2007 |
Rasilez® receives EU approval, the first major innovation in high blood pressure treatment for more than a decade |
| 18/08/2007 |
Reclast® receives US regulatory approval as first and only once-yearly treatment for women with postmenopausal osteoporosis |
| 16/08/2007 |
Novartis starts US shipment of Fluvirin® allowing for early influenza vaccination of millions of Americans |
| 10/08/2007 |
FDA grants additional six months marketing exclusivity for the high blood pressure medicine Diovan® |
| 06/08/2007 |
Novartis concerned Indian court ruling will discourage investments in innovation needed to bring better medicines to patients |
| 25/07/2007 |
Tasigna® approved in Switzerland based on impressive efficacy in patients with a form of leukemia no longer responding to Glivec® |
| 23/07/2007 |
Novartis completes its fourth share repurchase program |
| 20/07/2007 |
New data show Tekturna® and Diovan® used together provide additive blood pressure reductions |
| 19/07/2007 |
Exelon® skin patch recommended for European approval, the first use of this new technology to treat patients with Alzheimer's disease |
| 19/07/2007 |
Aclasta® recommended for European approval as the first once-yearly treatment for women with postmenopausal osteoporosis |
| 19/07/2007 |
Galvus®, a new oral treatment for type 2 diabetes, receives positive opinion recommending European Union approval |
| 17/07/2007 |
Novartis delivers strong performance in first half of 2007 (H1 - Report) |
| 09/07/2007 |
Exelon®Patch, the first and only skin patch for the treatment of Alzheimer's disease, receives first worldwide approval in US |
| 03/07/2007 |
Novartis plans 30% increase in US supplies of Fluvirin® influenza vaccines and delivery of 40 million doses for 2007/2008 season |
| 02/07/2007 |
Novartis completes divestment of Medical Nutrition business |
| 02/07/2007 |
Novartis enhances its vaccine pipeline by gaining access to Intercell's key technologies and vaccines programs |
| 25/06/2007 |
New data from multiple studies show Galvus® delivers consistent and robust blood sugar control in patients with type 2 diabetes |
| 22/06/2007 |
Sandoz receives positive EU opinion for approval of epoetin alfa biosimilar |
| 22/06/2007 |
Rasilez®, an important new treatment for high blood pressure, receives positive opinion recommending European Union approval |
| 21/06/2007 |
Exforge® receives final US approval as new and powerful treatment option for patients with high blood pressure |
| 15/06/2007 |
Prexige® study shows significantly less impact on blood pressure than ibuprofen in osteoarthritis patients with controlled hypertension |
| 13/06/2007 |
Novartis gains European approval for its innovative flu vaccine Optaflu® |
| 11/06/2007 |
US court allows Teva to resume US sales of its generic version of Lotrel |
| 04/06/2007 |
Study shows one year of Glivec® reduces risk of cancer returning by 82% following surgery for gastrointestinal stromal tumors |
| 29/05/2007 |
US court continues to prevent Teva from shipping any additional generic copies of the high blood pressure medicine Lotrel |
| 21/05/2007 |
Exforge® helps vast majority of patients effectively control their blood pressure after failing on other medicines, according to new clinical data |
| 21/05/2007 |
Single-tablet combination of Tekturna® and diuretic, an important new option for people with high blood pressure, submitted for US approval |
| 08/05/2007 |
Focetria®, the Novartis pandemic influenza vaccine, receives European Union approval |
| 30/04/2007 |
Sebivo® approved in European Union as a new first-line treatment for chronic hepatitis B |
| 27/04/2007 |
Optaflu®, the Novartis cell culture-derived influenza vaccine, receives positive opinion supporting European Union regulatory approval |
| 27/04/2007 |
Diovan® achieved 40% reduction in stroke and cardiovascular events in landmark Jikei Heart Study |
| 26/04/2007 |
Over 10 000 Novartis associates worldwide take part in Community Partnership Day |
| 25/04/2007 |
Novartis delivers 4.7 million treatments of anti-malarial medicine to Tanzania on Africa Malaria Day |
| 25/04/2007 |
Novartis expands portfolio of respiratory medicines by acquiring rights to a novel therapeutic vaccine against nicotine addiction |
| 23/04/2007 |
Novartis with dynamic growth in the 2007 first quarter (Q1 - Media release) |
| 23/04/2007 |
Novartis with dynamic growth in the 2007 first quarter (Q1 - Report) |
| 19/04/2007 |
Novartis expands late-stage oncology pipeline with AS1404, a novel agent shown to break down blood vessels that support tumor growth |
| 17/04/2007 |
Reclast® receives US approval as a highly effective treatment for patients with Paget's disease of the bone |
| 12/04/2007 |
Positive results prompt US National Cancer Institute to make Glivec® available to patients in post-surgical GIST study |
| 12/04/2007 |
Novartis completes its business portfolio restructuring, divesting Gerber for USD 5.5 billion to Nestlé |
| 30/03/2007 |
Novartis suspends US marketing and sales of Zelnorm(R) in response to request from FDA |
| 26/03/2007 |
Tekturna®, first new type of high blood pressure medicine in a decade, provides additional blood pressure reduction when used with Diovan® |
| 26/03/2007 |
Novartis to launch its own branded version of a leading multiple sclerosis therapy through agreement with Bayer Schering Pharma |
| 13/03/2007 |
Novartis ranked No. 1 among pharmaceutical companies in Fortune magazine's ''World's Most Admired Companies'' survey |
| 06/03/2007 |
Novartis shareholders approve all resolutions at 2007 Annual General Meeting, including dividend increase and Board elections |
| 06/03/2007 |
Tekturna® - the first new type of high blood pressure medicine in more than a decade - receives its first approval in the US |
| 03/03/2007 |
Novartis to market newly approved Procleix® Tigris® System in U.S. as the first fully automated system for West Nile virus blood screening |
| 02/03/2007 |
Sebivo® approved in China for treatment of chronic hepatitis B, the nation's second leading cause of death |
| 26/02/2007 |
Leading proxy advisory firm ISS recommends Novartis shareholders to approve all Board proposals at next Annual General Meeting |
| 26/02/2007 |
Novartis committed to making Galvus® available for patients with type 2 diabetes after US regulators issue ''approvable letter'' |
| 23/02/2007 |
Focetria® pandemic influenza vaccine receives positive European Union regulatory agency opinion supporting approval |
| 15/02/2007 |
Novartis seeking clarity in Indian patent laws, a critical incentive for long-term R&D investments into better medicines for patients |
| 12/02/2007 |
Novartis, The Broad Institute, and Lund University announce release of genome-wide analysis of genes associated with type 2 diabetes and related metabolic disorders |
| 09/02/2007 |
Novartis proposes approval of tenth consecutive higher dividend payment and election of new Board member at Annual General Meeting |
| 01/02/2007 |
Novartis files 2006 annual report on Form 20-Fwith the US Securities and Exchange Commission |
| 25/01/2007 |
Novartis Institute for Tropical Diseases inaugurates new Indonesian research initiative to study dengue fever, tuberculosis and malaria |
| 24/01/2007 |
Lucentis® receives approval in the European Union - the first drug to improve vision in patients with wet AMD, a leading cause of blindness |
| 18/01/2007 |
Exforge® approved in Europe as powerful new blood pressure therapy combining two leading medications in a single pill |
| 18/01/2007 |
Novartis strategic healthcare portfolio drives sustained strong performance with record full-year results in 2006 |
| 17/01/2007 |
Novartis receives US government contract to further develop a novel antigen technology that could extend vaccine supplies in a pandemic outbreak |
| 22/12/2006 |
Exforge® receives US regulatory approval as a new and highly effective treatment option for patients with high blood pressure |
| 14/12/2006 |
Novartis making significant progress in creating new strategic growth platform in human vaccines, names site for new division headquarters |
| 14/12/2006 |
Novartis to further focus on healthcare, reaching agreement to sell its Medical Nutrition business |
| 14/12/2006 |
Novartis announces three-month extension of US regulatory review period for Tekturna® |
| 11/12/2006 |
Pivotal submission data shows Tasigna® achieved impressive response rates in chronic myeloid leukemia patients no longer helped by Glivec® |
| 06/12/2006 |
Glivec® demonstrates highest five-year overall survival rate in history of treatment for patients with chronic myeloid leukemia |
| 06/12/2006 |
New evidence reinforces efficacy and tolerability of Galvus® as a new once-daily oral treatment option for patients with type 2 diabetes |
|
|
|
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis' website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
|
